We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Single Automated Analyzer to Bring Full Suite of Diagnostics to Wherever Patients Are

By LabMedica International staff writers
Posted on 09 May 2023
Print article
Image: The single automated device can run hematology, clinical chemistry, and immunoassays subsystems in parallel (Photo courtesy of Freepik)
Image: The single automated device can run hematology, clinical chemistry, and immunoassays subsystems in parallel (Photo courtesy of Freepik)

Timely and accurate diagnostics can enhance patient care by making it more informed, personalized, and proactive. Now, a novel platform that delivers swift results using minimal blood volumes incorporates technology that facilitates automation and adaptable form factors outside centralized labs, bridging the gap between diagnostics and treatment.

Vital Biosciences Inc. (Mississauga, ON, Canada) is developing a single automated device designed to provide a comprehensive range of diagnostics directly to patients. The company's technology strives to make healthcare significantly more personalized, proactive, and accessible. With only 600 uL of blood, the platform can measure 50+ of the most commonly requested biomarkers in primary care within 20 minutes, without compromising analytical performance. The instrument employs an automated microfluidic workflow to simultaneously run three subsystems: hematology, clinical chemistry, and immunoassays. The platform quantifies the complete panel of biomarkers using on-board optical readers and automated sample preparation and measurement procedures that require minimal user input. This makes the platform suitable for use in CLIA-waived settings.

Vital's initial menu caters to a broad range of potential use cases for the general population, including inflammation, cardiac markers, diabetes, liver disorders, lipid disorders, post-acute event monitoring, clinical trial monitoring, chronic disease management, and proactive lifestyle management. The company aims to create a comprehensive menu that covers 100% of the tests needed for at least 90% of patients, thereby eliminating the need to send tests to a centralized lab. Patients would no longer need to travel to a draw site or ship their samples to a centralized laboratory, nor wait for days to discuss their results with their healthcare provider. Patients who are likely to require bloodwork can provide their sample at check-in and receive results during their initial appointment. Bridging this care gap will make diagnostics more accessible and accelerate clinical decision-making.

Related Links:
Vital Biosciences Inc. 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.